TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$18.2b

TTY Biopharm Past Earnings Performance

Past criteria checks 2/6

TTY Biopharm has been growing earnings at an average annual rate of 4.5%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 6.5% per year. TTY Biopharm's return on equity is 17.5%, and it has net margins of 19.6%.

Key information

4.5%

Earnings growth rate

4.5%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate6.5%
Return on equity17.5%
Net Margin19.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25
Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07
TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19
TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10
What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25
How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Revenue & Expenses Breakdown

How TTY Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4105 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,7261,1241,659351
31 Mar 245,6131,1711,574330
31 Dec 235,5061,1291,599310
30 Sep 235,3941,1681,543293
30 Jun 235,2871,1301,546312
31 Mar 235,1911,1061,515345
31 Dec 225,0621,0941,440353
30 Sep 224,9971,1931,396350
30 Jun 224,7311,1091,360323
31 Mar 224,6098561,340295
31 Dec 214,5368321,338288
30 Sep 214,2707511,330267
30 Jun 214,2357201,382251
31 Mar 214,0928741,365253
31 Dec 204,2229241,388262
30 Sep 204,1306931,405274
30 Jun 204,2557871,369295
31 Mar 204,4458601,402300
31 Dec 194,4669001,375299
30 Sep 194,4471,2361,305320
30 Jun 194,2041,2631,264324
31 Mar 194,1101,4991,253358
31 Dec 184,0361,4611,242361
30 Sep 184,1021,6961,225332
30 Jun 184,2401,6311,210331
31 Mar 184,1731,3791,161294
31 Dec 174,0791,3451,116296
30 Sep 173,8741,0881,097322
30 Jun 173,7651,0231,079321
31 Mar 173,7951,1341,063340
31 Dec 163,7611,1931,038342
30 Sep 163,7331,5361,055354
30 Jun 163,6121,5651,035337
31 Mar 163,3891,3931,048317
31 Dec 153,1951,2111,053340
30 Sep 153,0581,1331,060328
30 Jun 152,9299861,080348
31 Mar 152,9698291,132370
31 Dec 142,9807801,191369
30 Sep 142,9761961,234394
30 Jun 142,995941,312400
31 Mar 142,9571241,315390
31 Dec 133,1105871,325384

Quality Earnings: 4105 has high quality earnings.

Growing Profit Margin: 4105's current net profit margins (19.6%) are lower than last year (21.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4105's earnings have grown by 4.5% per year over the past 5 years.

Accelerating Growth: 4105's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4105 had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).


Return on Equity

High ROE: 4105's Return on Equity (17.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies